Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.
Gennao Bio has raised $1.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Gennao Bio's investors include OrbiMed, Logos Capital, Surveyor Capital, CureDuchenne Ventures.
Gennao Bio is headquartered in New York, United States.
Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.
Gennao Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gennao Bio — Funding & Investors." VCBacked, December 22, 2021, https://www.vcbacked.co/company/gennao-bio. Accessed November 12, 2026.
VCBacked. (2021). Gennao Bio — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/gennao-bio
{{cite web |title=Gennao Bio — Funding & Investors |url=https://www.vcbacked.co/company/gennao-bio |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Gennao Bio? Request a listing update